Loading patent…
AssigneesThe University of North Carolina at Chapel Hill, The Johns Hopkins University
InventorsSamuel Lai, Ying-Ying Wang, Arthi Kannan, Kennetta Nunn, Durai Babu Subramani, Richard Cone
Estimating the term…
The presently-disclosed subject matter relates to antibodies, compositions, and methods for inhibiting and treating pathogen infection and providing contraception. In particular, the presently-disclosed subject matter relates to inhibiting and treating pathogen infection and providing contraception in a subject using compositions and antibodies capable of trapping pathogens or sperm in mucus, thereby inhibiting transport of pathogens or sperm across mucus secretions. The subject matter further relates to methods for monitoring the effectiveness of vaccines by detecting antibodies capable of trapping pathogens in mucus.
An aerosol composition comprising a population of a human or humanized IgG monoclonal antibody directed against a virus that causes a respiratory disease, each antibody in the population comprising an oligosaccharide at a glycosylation site, the population comprising glycosylation patterns that enhance trapping potency of the antibody in mucus, wherein the antibody specifically binds an epitope of the virus, and wherein at least 30% of the antibodies in the population have a glycosylation pattern comprising the biantennary core glycan structure Manα1-6(Manα1-3)Manβ1-4GlcNAcβ1-4GlcNAcβ1 with terminal N-acetylglucosamine on each branch.
An aerosol composition comprising a population of a human or humanized IgG monoclonal antibody directed against a virus that causes a respiratory disease, each antibody in the population comprising an oligosaccharide at a glycosylation site, the population comprising glycosylation patterns that enhance trapping potency of the antibody in mucus, wherein the antibody specifically binds an epitope of the virus, and wherein the population comprises a sufficient amount of antibody having a glycosylation pattern comprising the biantennary core glycan structure Manα1-6(Manα1-3)Manβ1-4GlcNAcβ1-4GlcNAcβ1 with terminal N-acetylglucosamine on each branch for the concentration of the antibody having a glycosylation pattern comprising the biantennary core glycan structure Manα1-6(Manα1-3)Manβ1-4GlcNAcβ1-4GlcNAcβ1 with terminal N-acetylglucosamine on each branch in mucus after administration to a subject to be at least about 1 μg/ml.
An aerosol composition comprising a population of a human or humanized IgG monoclonal antibody directed against a virus that causes a respiratory disease, each antibody in the population comprising an oligosaccharide at a glycosylation site, the population comprising glycosylation patterns that enhance trapping potency of the antibody in mucus, wherein the antibody specifically bind an epitope of the virus, and wherein the population comprises a sufficient amount of antibody having a glycosylation pattern comprising the biantennary core glycan structure Manα1-6(Manα1-3)Manβ1-4GlcNAcβ1-4GlcNAcβ1 with terminal N-acetylglucosamine on each branch to trap the virus in mucus after administration to a subject.
Dependencies are inferred from the claim text.